Morgan Stanley assumed coverage of Regenxbio (RGNX) with an Overweight rating and $22 price target The firm appreciates the attractiveness of gene therapy in concept for VEGF-mediated diseases given the unmet need, but cautions that subretinal delivery may limit commercial uptake and suprachoroidal delivery data presented to date is still early. The analyst says the first functional results for RGX-202 in Duchenne muscular dystrophy will be shared in a company webcast on Monday.
Education
About Us
Working with TipRanks
Follow Us
1